Drugs / inactivated poliomyelitis vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04481191 | Aug 2020 → May 2021 | Rotavirus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | inactivated poliomyelitis vaccine | “three doses of an oral, live, pentavalent rotavirus vaccine (RV5) and three doses of an intramuscular, inactivated poliomyelitis vaccine (IPV) in 400 healthy infants” PMID 38509699 ↗ Mar 2024 |
| Known as | IPV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04481191 ↗ |
| Modality | Vaccine | “three doses of an oral, live, pentavalent rotavirus vaccine (RV5) and three doses of an intramuscular, inactivated poliomyelitis vaccine (IPV) in 400 healthy infants” PMID 38509699 ↗ Mar 2024 |
| Route | Intramuscular | “0.5 mL dose IPV (Sabin strain based), administered via IM injection” NCT04481191 ↗ |